Designing Selective Multi-Immune Cell Targeting LVVs with No Off-Target Delivery for In Vivo CAR-Ts Against Solid Tumours
11:15 am - Wednesday 10th February 2027
- Engineering immune cell-targeted lentiviral vectors to enable selective in vivo CAR-T engineering while minimising offtarget transduction and associated safety risks
- Targeting multiple immune cell types to combat solid tumours
- Advancing a next-generation in vivo platform to broaden patient access to transformative cell therapies
